An analysis of population data on cancer incidence, survival, and mortality revealed that early interventions and improvements to treatments contributed to a 26% decline in cancer deaths from 1991 to 2015.
First-line chemotherapy in combination with bevacizumab, compared with chemotherapy alone, may benefit patients with ovarian cancer and elevated neutrophil-to-lymphocyte ratios.
No significant difference was identified in combination CA125/CEA ratio vs CEA alone in distinguishing ovarian neoplasms from ovarian metastases.
Study patients who received Avastin plus chemotherapy followed by Avastin alone, had a greater median PFS vs patients who received chemotherapy alone (18.2 months vs 12 months; hazard ratio [HR] 0.62, 95% CI, 0.52-0.75; P<.0001).
Mirvetuximuab soravtansine uses a humanized FRα-binding antibody to target antibody-drug conjugates specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.
A prophylactic, graded, extended infusion of carboplatin, compared with a shorter, standard infusion, is not associated with a reduced rate of HSRs in women with recurrent ovarian cancer.
In a case study, olaparib was found to induce folate deficiency in most patients with relapsed ovarian cancer. Researchers discuss the significance of this adverse effect and how it was managed.
For patients with platinum-sensitive recurrent ovarian cancer, trabectedin plus PLD may be beneficial.
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Advanced Ovarian Cancer Survival Rates Longer After Primary Cytoreductive Surgery Compared With Neoadjuvant ChemotherapyApril 12, 2018
Researchers found a superior survival rate in patients who received primary cytoreductive surgery as opposed to neoadjuvant chemotherapy for stage IIIC and IV high-grade serous ovarian carcinoma.
The FDA has approved Rubraca, a poly (ADP-ribose) polymerase inhibitor, to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Genetic mutations assays using PapSEEK may facilitate the detection of certain cancers using fluids from Pap tests.
Vigil immunotherapy is possible for women with recurrent ovarian cancer and PARP 7 may impact ovarian cancer survival, according to two studies presented in New Orleans.
For patients with ovarian cancer taking pegylated liposomal doxorubicin who have hand-foot syndrome, frozen gloves and socks is a safe method of treatment.
The incidence of ovarian cancer was not related to metformin or statin usage among women with type 2 diabetes.
The disease allele may be passed from affected grandmother to granddaughter through the father's inherited genes.
The use of oral contraceptives did not reduce the risks of breast cancer or colorectal cancer.
Past epidemiological investigations resulted in inconsistent reports on the affiliation between antidepressants and the risk of ovarian cancer.
The USPSTF has issued an updated recommendation statement on ovarian cancer screening.
The addition of HIPEC resulted in longer recurrence-free and overall survival among patients with ovarian cancer.
A multi-analyte blood test, CancerSEEK, can detect 8 common cancer types, with high sensitivity and specificity.
The USPSTF states that the harms of screening for ovarian cancer in asymptomatic women outweigh the benefits.
Using powder makeup containing talc may increase the risk of ovarian cancer.
For hereditary breast, ovarian cancer, multigene testing can influence clinical treatment options.
For women with ovarian cancer, reducing chemotherapy dose was linked to worse survival regardless of BMI.
Regular low-dose aspirin use lowered ovarian cancer risk by 20% in 12 studies involving nearly 20,000 women.